Tim Smith

After his review on recent literature, Zirwas’s Maui Derm NP+PA Fall interview featured a discussion about the biggest unmet needs among patients.

This interview featured a literature review discussion about non-FDA approved advancements in dermatology, including oral roflumilast for psoriasis, metformin for acne, and minoxidil for nails.

In this interview segment, Chovatiya highlights HS therapies such as IL-17 inhibitors and JAK inhibitors, as well as unmet needs of patients.

This interview with Chovatiya highlights promising therapies in the dermatology space for the treatment of patients with the skin condition HS.

In this Maui Derm fall conference session, Callender highlights approaches to pigmentation issues such as vitiligo, melasma, and other disorders.

These poster data highlight that atopic dermatitis treatment may be suboptimal in certain patients, demonstrating the necessity of additional effective therapy options.

These real-world data resulted from an interim analysis of the PSoSA study on psoriasis patients with scalp itch, nail pain, and quality of life impairment.

These poster data presented at the Maui Derm Fall 2024 conference highlight changes in laboratory parameters for patients using the TYK2 inhibitor deucravacitinib.

This is an overview of our upcoming Maui Derm NP+PA Fall 2024 Program conference coverage.

Eli Lilly’s announcement of the lebrikizumab-lbkz approval for patients 12 years of age and older follows positive findings from the ADvocate 1, ADvocate 2, and ADhere studies.

This approval expands the drug’s age range and follows recent positive phase 3 findings on dupilumab treatment for patients aged 12 to 17 with CRSwNP.

In this analysis, an increased risk of allergy and eczema was associated with bread and thiamine intake increases during pregnancy.

These data highlighted dupilumab’s potential as a means to break the ‘itch–scratch cycle’ in those with chronic prurigo, with disease remission induced in a subset.

This marketing authorization by the FDA allows the Hearing Aid Feature to be implemented alongside compatible Apple AirPod Pro headphones.

This analysis may help to inform research evaluating the value of obstructive sleep apnea treatments designed to minimize cardiovascular risk as well as related deaths among older patients.

In this survey, investigators sought to develop a definition for eczema flare which was patient-centered and based upon consensus.

These data may provide invaluable insights, given the lack of reliable methods for identifying newborns with increased risk of developing eczema.

These findings also highlight that an early response to alopecia areata treatment can be identified with trichoscopy.

These findings resulted from a systematic literature review highlighting the impact of stigma and lack of support on self-image for patients with eczema, psoriasis, HS, and other conditions.

These data on depemokimab, a long-acting asthma treatment, suggest the medication reduces serious attacks by more than half and strongly reduces asthma exacerbations.

These data may help to inform and guide clinicians as well as policymakers in their allocation of efficient chronic urticaria management resources.

These real-world findings highlight the benefits of sustained dupilumab therapy for individuals with chronic rhinosinusitis with nasal polyps.

In this analysis, the differences in adverse events resulting from JAKi among adults and children were evaluated.

These findings further endorse the need for health care quality improvements for veterans, given the rates of melanoma, skin cancer, and psoriasis.

These data were presented at the European Society of Contact Dermatitis congress, with findings drawn from the CHECK and RWEAL studies on chronic hand eczema.

This Month in Review summarizes some of the most significant stories covered in the month of August in the pulmonary health space, including new research and FDA news.

In this review of August 2024, the editorial team highlighted major stories from the previous month related to FDA approvals and medications for atopic dermatitis and psoriasis.

These Mendelian analysis results highlight an association between alopecia areata and asthma, indicating a mediating role of IL-33.

These data suggest that there are a subset of individuals with complete skin clearance of their psoriasis who report residual effects of their condition.

These data suggest the necessity of caution when clinicians treat select patient groups with dupilumab for atopic dermatitis.